• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intact Vascular finishes patient enrollment for angioplasty clinical trial

March 23, 2017 By Sarah Faulkner

Intact Vascular finishes patient enrollment for angioplasty clinical trialIntact Vascular said today that it finished enrollment for the Toba II clinical trial evaluating its Tack Endovascular System in combination with standard or drug coated balloon angioplasty in arteries above the knee.

The company’s trial enrolled 210 patients and will focus on the superficial femoral artery and the proximal segment of the popliteal artery, according to Intact.

The Tack system is used to repair tears in the artery walls that occur as a complication of angioplasty. The system allows healthcare providers repair tears without leaving as much foreign material in the artery, while reducing mechanical stress and preserving future treatment options, the company said.

“TOBA II is a unique clinical study which will give us important insights into a new approach to dissection repair that holds great promise for advancing the endovascular treatment of peripheral artery disease,” principal investigator Dr. William Gray said in prepared remarks.”I extend my sincere appreciation and congratulations to all of the investigators and their teams for making the timely achievement of this milestone possible.”

The trial will make use of standard balloon angioplasty and drug coated balloon angioplasy with C.R. Bard‘s (NYSE:BCR) Lutonix DCB. Its primary endpoint is duplex-derived patency at 12-months after treatment.

Intact said it is also sponsoring a trial in Europe that is investigating the use of the Tack system with Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB.

“The Tack Endovascular System was conceived as a minimal metal approach to dissection repair, and that idea has become even more important with the advent of drug coated balloon angioplasty,” Intact co-founder & chief medical officer Dr. Peter Schneider added. “The completion of TOBA II enrollment is an exciting step toward FDA approval and ultimately making the Tack Endovascular System broadly available to patients suffering from peripheral arterial disease.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: C.R. Bard, Intact Vascular, Medtronic

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS